Clinical trial
Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering…
NCT00160550 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00160550 |
|---|---|
| Title | Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures |
| Official title | A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Pediatric Subjects (4-65 Years) Suffering From… |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Convulsive Epilepsy |
| Intervention type | Drug |
| Interventions | Levetiracetam |
| Enrollment | 154 |
| Start date | Sep 1, 2001 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 26, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: